MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Health Systems, Economic Evaluations, Quality of Life
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

6,862 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
6,862 works in the cohort · of 4,299,418page 88 of 138

Labels cover 97 of 6,862 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 6,862 of 6,862 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
Health Economics in Clinical Research
Braden Manns
2015· article· en· Methods in molecular biology· Economics, Econometrics and Finance
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
Should we ever stop clinical trials for efficacy?
Nicholas A. Fergusson, Donald Griesdale
2018· letter· en· Canadian Journal of Anesthesia/Journal canadien d anesthésie· Economics, Econometrics and Finance
machine prediction:candidate · metaresearchconsensus · none
1
citations
affno abstractunlabeled
Health-Related Quality of Life
2014· book-chapter· en· Economics, Econometrics and Finance
machine prediction:candidate · noneconsensus · none
1
citations
affaboutunlabeled
Access to newer medications.
Rajamannar Ramasubbu
2011· article· en· PubMed· Economics, Econometrics and Finance
machine prediction:candidate · noneconsensus · none
1
citations
aboutno affunlabeled
PP04 Co-Constructing Recommendations With Patients And Health Professionals
Laurie Lambert, Lucy J. Boothroyd, L. Azzi, Caroline Collette, Philippe Brouillard, Marie‐Pascale Pomey +6 more
2018· article· en· International Journal of Technology Assessment in Health Care· Economics, Econometrics and Finance
machine prediction:candidate · noneconsensus · none
1
citations
affunlabeled
Reference drug pricing
Aslam H. Anis
2002· article· en· Europe PMC (PubMed Central)· Economics, Econometrics and Finance
machine prediction:candidate · noneconsensus · none
1
citations
affaboutgemma · no categorygpt · no categorymodels agree
Real-world cost-effectiveness of pertuzumab (P) with trastuzumab + chemo (T+Chemo) in patients (pts) with metastatic breast cancer (MBC): A population-based retrospective cohort study by the Canadian Real-world Evidence for Value in Cancer Drugs (CanREValue) collaboration.
Wei Fang Dai, Jaclyn Beca, Chenthila Nagamuthu, Ning Liu, Maureen Trudeau, Craig C. Earle +2 more
2021· article· en· Journal of Clinical Oncology· Economics, Econometrics and Finance
machine prediction:candidate · noneconsensus · none
1
citations

How this was built: Screen · Findings · About